Summary Box: J&J defends insulin pumps amid probe

FDA PROBE: The Food and Drug Administration tells Johnson & Johnson it could face fines over selling insulin pumps with faulty keypads and not promptly reporting serious injuries to diabetics using its OneTouch Ping and 2020 pumps.

COMPANY RESPONSE: J&J's Animas unit says the injured patients didn't follow pump directions and the keypads weren't a risk to people. It will soon respond to FDA's demand to correct violations.

QUALITY LAPSES: It's at least the seventh J&J business in the last 2 1/2 years to run into problems with the FDA or recall products with safety or quality issues.